Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.30 USD
Change Today -1.07 / -16.86%
Volume 6.2K
ISCOD On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCOD) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/14 - $19.20
52 Week Low
07/29/15 - $5.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

international stem cell corp (ISCOD) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCOD) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCOD) Details

International Stem Cell Corporation, a biotechnology company, focuses on development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. It develops cell types, including neural stem cells for the treatment of Parkinson’s disease and other neurological disorders; liver cells to treat various congenital and acquired liver diseases; islet cells for treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company’s human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a branded Website, professional channels, and distributors; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 03/30/15
Founded in 2001

international stem cell corp (ISCOD) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $246.1K
Chief Scientific Officer and Director
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2014.

international stem cell corp (ISCOD) Key Developments

International Stem Cell Corporation Announces Conclusion of Employment of John Simon Craw, Executive Vice President of Business Development on June 5, 2015

On June 3, 2015, International Stem Cell Corporation and Dr. John Simon Craw, the company's executive vice president of business development, agreed that Dr. Craw's employment status would conclude on June 5, 2015. The company and Dr. Craw acknowledged that the major projects for which Dr. Craw had been engaged had been completed, and that his services as an employee were no longer needed. Dr. Craw will receive a severance payment of $55,000 and he will continue to assist the company in a consulting capacity following the conclusion of his employment.

International Stem Cell Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

International Stem Cell Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $1,622,000 against $1,649,000 a year ago. Loss from operating activities was $1,966,000 against $2,065,000 a year ago. Loss before income taxes was $1,287,000 against $1,435,000 a year ago. Net loss applicable to common stockholders was $1,287,000 or $0.01 per basic and diluted share against $1,435,000 or $0.01 per basic and diluted share a year ago.

International Stem Cell Corporation Announces Resignation of Jay Novak as Chief Financial Officer, Effective May 8, 2015

On April 27, 2015, Jay Novak, the Chief Financial Officer of International Stem Cell Corporation announced his resignation from the Company, effective May 8, 2015. Mr. Novak is pursuing a new career opportunity in the biotechnology industry and has indicated that his resignation did not result from any disagreement with the Company's operations, policies or practices.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCOD:US $5.30 USD -1.07

ISCOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.10 USD -0.01
Bioheart Inc $0.0063 USD 0.0001
Cytori Therapeutics Inc $0.44 USD 0.00
Nuo Therapeutics Inc $0.19 USD -0.0099
StemCells Inc $0.42 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ISCOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 224.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at